Satomi Takei

Dr. Satomi Takei

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
STSatomi Takei
Satomi Takei
KTKanae Teramoto
Kanae Teramoto
YSYuji Sekiguchi
Yuji Sekiguchi
TMTakashi Miida
Takashi Miida
TKTeruo Kirikae
Teruo Kirikae
YTYoko Tabe
Yoko Tabe
Elizabethkingia species, isolated from clinical and environmental samples, are emerging opportunistic bacterial pathogens with a high mortality rate in clinical settings worldwide. Taxonomically, Elizabethkingia comprises seven species: E. anophelis , E. argenteiflava , E. bruuniana , E. meningoseptica , E. miricola , E. ursingii , and E. occulta . In this study, we identified useful biomarker proteins, including ribosomal L29, L30, S21, and the YtxH domain-containing proteins, for distinguishing Elizabethkingia species using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) profiles. Evaluation of 29 clinical and environmental Elizabethkingia strains revealed that these species could be separated by MALDI-TOF MS profiles into six groups —E. anophelis , E. argenteiflava , E. bruuniana/E. miricola , E. meningoseptica , E. ursingii , and E. occulta —based on the four biomarker protein peaks. This study demonstrates the potential of routine MALDI-TOF MS -based examination methods for the early detection of Elizabethkingia species in clinical laboratories. IMPORTANCE: Elizabethkingia species are groups of emerging opportunistic bacterial pathogens with a high mortality rate, causing healthcare-associated outbreaks worldwide. Rapid identification of Elizabethkingia species is important becausethese species show intrinsically carbapenem resistance and there are few data for using appropriate antibiotics. Until now, only whole-genome sequencing could accurately identify the seven Elizabethkingia species. Therefore, establishing rapid and accurate identification methods for Elizabethkingia species in clinical laboratories is vital. In this study, we developed new methods for identifying Elizabethkingia species using four biomarker protein peaks-ribosomal L29, L30, S21, and the YtxH domain-containing proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) proteotyping. This study demonstrates the potential of routine MALDI-TOF MS -based laboratory examination for the early identification of Elizabethkingia species.

15 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
STSatomi Takei
Satomi Takei
TATomohiko Ai
Tomohiko Ai
TYTakamasa Yamamoto
Takamasa Yamamoto
GIGene Igawa
Gene Igawa
TKTakayuki Kanno
Takayuki Kanno
Yoko TabeYoko Tabe
Yoko Tabe
Quantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S can be used to predict neutralizing activities in patients’ serums using an authentic virus neutralization assay. One hundred forty-six serum samples were obtained from 59 patients with COVID-19 at multiple time points. Of the 59 patients, 44 cases were included in Group M (mild 23, moderate 21) and produced 84 samples (mild 35, moderate 49), while 15 cases were included in Group S (severe 11, critical 4) and produced 62 samples (severe 43, critical 19). The neutralization assay detected 73% positive cases, and Elecsys® anti-S and Elecsys® Anti-SARS-CoV-2 (Elecsys® anti-N) showed 72% and 66% positive cases, respectively. A linear correlation between the Elecsys® anti-S assay and the neutralization assay were highly correlated (r = 0.7253, r2 = 0.5261) than a linear correlation between the Elecsys® anti-N and neutralization assay (r = 0.5824, r2 = 0.3392). The levels of Elecsys® anti-S antibody and neutralizing activities were significantly higher in Group S than in Group M after 6 weeks from onset of symptoms (p < 0.05). Conversely, the levels of Elecsys® anti-N were comparable in both groups. Three immunosuppressed patients, including cancer patients, showed low levels of anti-S and anti-N antibodies and neutralizing activities throughout the measurement period, indicating the need for careful follow-up. Our data indicate that Elecsys® anti-S can predict the neutralization antibodies in COVID-19.

15 May 2024 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
STSatomi Takei
Satomi Takei
YTYoko Tabe
Yoko Tabe
TMTakashi Miida
Takashi Miida
THTomomi Hishinuma
Tomomi Hishinuma
AKAbdullah Khasawneh
Abdullah Khasawneh
TTTatsuya Tada
Tatsuya Tada
The emergence of multidrug-resistant Klebsiella pneumoniae has become a serious problem in medical settings worldwide. A total of 46 isolates of multidrug-resistant K. pneumoniae were obtained from 2 hospitals in Nepal from October 2018 to April 2019. Most of these isolates were highly resistant to carbapenems, aminoglycosides and fluoroquinolones with the minimum inhibitory concentrations (MICs) of more than 64 μg/mL. These isolates harbored carbapenemase-encoding genes, including blaNDM-1, blaNDM-5, blaOXA-181 and blaOXA-232, and 16S rRNA methyltransferase-encoding genes, including armA, rmtB, rmtC and rmtF. Multilocus sequence typing revealed that 44 of 46 isolates were high-risk clones such as ST11 (2%), ST14 (4%), ST15 (11%), ST37 (2%), ST101 (2%), ST147 (28%), ST231 (13%), ST340 (4%) and ST395 (28%). In particular, ST395 isolates, which spread across medical settings in Nepal, co-harbored blaNDM-5 and rmtB on IncFII plasmids and co-harbored blaOXA-181/-232 and rmtF on ColKP3 plasmids. Several isolates harbored blaOXA-181 or blaNDM-5 on their chromosomes and multi-copies of blaNDM-1 or genes encoding 16S rRNA methyltransferases on their plasmids. The presented study demonstrates that the high-risk clones of multidrug-resistant K. pneumoniae spread in a clonal manner across hospitals in Nepal.

16 December 2025 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MKMaiko Kirikae
Maiko Kirikae
STSatomi Takei
Satomi Takei
THThi Thi Htoon
Thi Thi Htoon
PSPan Ei Soe
Pan Ei Soe
NHNang Sarm Hom
Nang Sarm Hom
TTTatsuya Tada
Tatsuya Tada
Tigecycline is one of the last-resort antibiotics for treating serious infections caused by multidrug-resistant pathogens. This is the first report of clinical isolates of tigecycline-resistant Escherichia coli harboring tet(X4) in Myanmar. Two E. coli isolates were obtained from two patients at two hospitals in Myanmar from November 2023 to May 2024. They were identified using MALDI-TOF MS, and minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Genomic DNA was extracted and sequenced using next generation sequencing. Drug-resistance factors were determined, and the genetic environments surrounding tet(X4) and blaNDM-5 were analyzed. Conjugation rates of plasmids harboring tet(X4) and blaNDM-5 were calculated. One strain, TGH62, was resistant to tigecycline (MIC 8 µg/ml) and meropenem (MIC 128 µg/ml), whereas the other, YGH433, was resistant to tigecycline (MIC 4 µg/ml). Whole-genome sequencing revealed that both strains harbored tet(X4) on plasmids and TGH62 also harbored blaNDM-5 on a plasmid. The plasmids carrying tet(X4) in TGH62 and YGH433 belonged to the IncI and IncFII incompatibility groups, respectively. The plasmid carrying blaNDM-5 belonged to the IncFIA incompatibility group. The conjugation efficiencies of the plasmids harboring tet(X4) in YGH433 and blaNDM-5 in TGH62 were relatively high, whereas that harboring tet(X4) in TGH62 was low. Tigecycline-resistant Enterobacteriaceae harboring tet(X4) may spread in hospitals in Myanmar. Further studies are needed to detect tet(X4) conferring tigecycline resistance in hospitals as well as environmental settings in Myanmar.

1 January 2023 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
JKJonghun Kim
Jonghun Kim
THToshio Hasegawa
Toshio Hasegawa
KTKurisu Tada
Kurisu Tada
YUYuki Uehara
Yuki Uehara
YFYukiko Fukui
Yukiko Fukui
SIShigaku Ikeda
Shigaku Ikeda
Kim J, et al. Ann Dermatol. 2023 May;35:e45. https://doi.org/10.5021/ad.21.077

23 May 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
RFRuna Furuya
Runa Furuya
STSatomi Takei
Satomi Takei
Yoko TabeYoko Tabe
Yoko Tabe
AAAnthony Ablordey
Anthony Ablordey
RSRyoichi Saito
Ryoichi Saito
Brucella intermedia, a gram-negative, non-lactose-fermenting, aerobic, rod-shaped bacterium, is found in environmental sources (e.g., soil and water). In 2020, Ochrobactrum was reclassified as Brucella. We conducted a genomic analysis of B. intermedia from hospital wastewater samples in western Ghana. A hybrid genome assembly was constructed integrating short-read data from DNA Nanoball sequencing with long-read sequences generated by Oxford Nanopore MinION technology. Identification and antimicrobial susceptibility profiles were determined using MicroScan autoSCAN-4 based on Clinical and Laboratory Standard Institute documents. ResFinder and CARD Resistance Gene Identifier (RGI) were used to identify antimicrobial resistance (AMR) genes, and BLAST and VFDB datasets were used to identify virulence factor genes. The complete genome had two chromosomes, no plasmid, and a high average nucleotide identity value (98.05%) with B. intermedia. Resistance to trimethoprim-sulfamethoxazole was revealed, the first report in this species. CARD RGI revealed the presence of AMR genes, including ANT(9)-Ic and adeF. Local BLAST analysis revealed Cgs, a B. melitensis virulence factor. B. intermedia is an opportunistic human pathogen clinically isolated several times, suggesting the importance of accurately identifying multidrug resistance. B. intermedia may possess virulence factors similar to those of B. melitensis. Further study is needed to fully elucidate its pathogenesis.